Our 2023 Experts Included:

Harness Promising Novel Targets & Advance More Durable Treatment in the Clinic to Deliver Best-in-Class Remittive Therapeutics in Chronic Dermatological Indications

Welcome to the 7th Dermatology Drug Development Summit for Inflammatory Skin Diseases

The Dermatology Drug Development Summit returned for its 7th year as the largest industry focused summit dedicated to advancing treatment options across Atopic Dermatitis, Alopecia Areata, Hidradenitis suppurativa, Prurigo Nodularis and Vitiligo to name a few.

From improving the safety profile of JAK inhibitors to opening the doors to maintenance therapies and cracking the first approved therapies in rare dermatological diseases, these strategic and progressive conversations are not ones to be missed.

This summit provided optimal opportunity to meet with 120+ key opinion leaders from LEO Pharma, AbbVie, Janssen, Sanofi, Almirall, GSK, BMS, Incyte, Dermavant and more to accelerate dermatology pipelines and work towards achieving durable therapies following the success in attaining remittive therapy in Psoriasis.

Our 2023 Speaker Faculty Included:

2023's Presenting Companies Included:

Copy of 34048 Animated DDD Speaker Companies

Testimonials from the Dermatology Drug Development Summit

leo pharma logo

High quality conference providing insights on the opportunities and challenges in dermatology drug development” 

gsk logo

I was able to get something out of each presentation. It was a total success in my opinion.” 

Our 2023 Partners:

Lead and Hosting Partner

Expertise Partners

Hosting Partner

Innovation Partners

Exhibition Partners

Event Partner

Industry Partner